Trump reportedly to form health funding board that could veto ‘woke’ initiatives

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-21 • Permanent link

Rumors of a potential power shift in the US healthcare landscape have been swirling in recent days, as President Donald Trump is reportedly set to establish a new health funding board. According to sources close to the White House, the board will be responsible for approving NIH funding and aligning it with Trump's agenda. The move has sent shockwaves through the healthcare industry, with many investors and experts expressing concern over the potential implications for healthcare research and development. Market analysts have also noted that the move could lead to a significant shift in the balance of power between the Trump administration and Congress.

Fears of a "woke" agenda are also driving concerns among some investors, who worry that the new board will prioritize ideological over scientific considerations in funding decisions. The potential for vetoes and delays in funding could have far-reaching consequences for the development of new treatments and therapies, and may disproportionately affect marginalized communities that rely on government-funded healthcare programs. As a result, investors are bracing themselves for a potentially turbulent period in the healthcare sector.

The move is seen as a key component of Trump's broader efforts to reshape the US healthcare system, which have been shaped by decades of partisan gridlock and ideological divisions. Historically, NIH funding has been a key driver of medical research, with many groundbreaking treatments and therapies emerging from government-funded studies. However, the agency has also faced criticism for its perceived lack of transparency and accountability, with some arguing that it is too beholden to special interests and political agendas.

As the new board begins to take shape, investors and experts will be watching closely for signs of how it will operate and what kinds of decisions it will make. With the potential for vetoes and delays in funding, the next few months are likely to be marked by significant uncertainty and volatility in the healthcare sector. Meanwhile, the broader implications of the move for the US healthcare system and the global economy will remain to be seen, but one thing is clear: the stakes have never been higher.